Cipla EU to invest € 15 million in Ethris
Cipla and Ethris partner for the development of mRNA-based therapies
Cipla and Ethris partner for the development of mRNA-based therapies
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Subscribe To Our Newsletter & Stay Updated